Lag0s:
|
Healthcare
Week Summary
Technology
  • Earth has captured a temporary 'second moon,' a small asteroid named 2024 PT5, which will orbit until November 2024.
  • Research indicates that larger AI chatbots are increasingly prone to generating incorrect answers, raising concerns about their reliability.
  • Meta's Chief Technical Officer discussed advancements in AR and VR technologies, particularly focusing on the Orion AR glasses.
  • The author reflects on their experience with Rust, proposing several changes to improve the language's usability and safety features.
  • The Tor Project and Tails OS have merged to enhance their efforts in promoting online anonymity and privacy.
  • OpenAI is undergoing leadership changes, with key executives departing amid discussions about restructuring and the company's future direction.
  • Git-absorb
  • The concept of critical mass explains how significant changes occur when a threshold of acceptance is reached, impacting technology and society.
  • WordPress.org has banned WP Engine from accessing its resources due to ongoing legal disputes, raising concerns about security for WP Engine customers.
  • PostgreSQL 17
  • Hotwire Native is a web-first framework that simplifies mobile app development, allowing developers to reuse HTML and CSS across platforms.
  • Radian Aerospace is progressing on a reusable space plane, completing ground tests and aiming for full-scale flights by 2028.
  • A groundbreaking diabetes treatment using reprogrammed stem cells has enabled a patient to produce insulin independently for over a year.
  • Apple is developing a new home accessory that combines features of the iPad, Apple TV, and HomePod, expected to launch in 2025.
  • SpaceX's Starlink service is set to surpass 4 million subscribers, reflecting rapid growth and significant revenue projections.
  • TinyJS is a lightweight JavaScript library that simplifies dynamic HTML element creation and DOM manipulation for developers.
  • Article highlights concerns of AI in healthcare, advocating for patient-led research and participatory ML.

    AI advancements in healthcare raise concerns about overlooking patient perspectives and deepening inequalities. Automated decision-making systems often deny resources to the needy, demonstrating biases that could propagate into AI-driven medicine. This article advocates for participatory machine learning and patient-led research to prioritize patient expertise in the medical field.

    Hi Impact
    AIHealthcare
    Tuesday, March 12, 2024
  • Moderna's mRNA cancer vaccine shows promising trial results for melanoma and head and neck cancer, boosting survival rates.

    Moderna's mRNA cancer vaccine, developed to target melanoma, might also treat a form of head and neck cancer. Data from an early trial showed a greater survival rate for patients who took Moderna's cancer vaccine alongside immunotherapy treatments. The news sent Moderna's share price soaring.

    Hi Impact
    ModernamRNA cancer vaccineHealthcare
  • New 'smart' antibiotic effectively targets deadly bacteria without harming the microbiome.

    Gram-negative bacteria are often hardy, virulent, and quick to evolve resistance to antibiotics. Scientists have developed an antibiotic that kills pathogenic Gram-negative bacteria without impairing the gut microbiome. Still untested in humans, the compound's usefulness will depend on whether the bacteria will develop resistance to it in the long run. The time from an antibiotic's discovery to its approval for clinical use can be more than two decades, and there is not much money to be made with a novel antibiotic - around ten to twenty new Gram-negative antibiotics have been discovered in the past decade but none have gained approval from the US FDA.

    Hi Impact
    Healthcare
  • Experimental Alzheimer's drug donanemab shows promise in slowing disease progression.

    The experimental drug donanemab slowed the progression of Alzheimer's disease by about 35% in a study of more than 1,700 people. Eli Lilly, the company that makes the drug, has submitted the results of its study to the Food and Drug Administration, which is expected to make a decision on the drug by the end of the year. The drug is still not a cure - its benefits amount to only about a seven-month delay in the loss of memory and thinking. The drug caused dangerous swelling or bleeding in the brain in about 25% of patients.

    Hi Impact
    Eli LillydonanemabHealthcare
  • New HIV prevention drug, lenacapavir, shows 100% efficacy in clinical trial, with plans for regulatory submission.

    A twice-yearly injection of a new pre-exposure prophylaxis drug was shown to provide young women total protection from HIV infection in a large clinical trial performed in South Africa and Uganda. The drug, lenacapavir, works by interfering with the protein shell that protects HIV's genetic material and the enzymes needed for replication. Gilead Sciences plans to submit the drug for approval with a number of country regulators within the next couple of months. It will offer licenses to companies that make generic drugs to help get prices down.

    Hi Impact
    Gilead ScienceslenacapavirSouth Africa, UgandaHealthcare
  • PA-LLaVA, a language-vision assistant for pathology image analysis.

    PA-LLaVA is a domain-specific language-vision assistant designed for pathology image analysis.

    Hi Impact
    PA-LLaVAHealthcare
  • Vertex Pharmaceuticals' new pain drug Suzetrigine shows promise in targeting pain-sensing neurons.

    Vertex Pharmaceuticals is currently seeking regulatory approval for a new drug that looks promising in clinical trials. Suzetrigine could be the first of an entirely new class of pain therapy. It targets specific sodium ion channels found on pain-sensing nerve cells. While the effect of the drug is modest, it demonstrates that the strategy of targeting sodium channels specific to pain-sensing neurons works, leading to hope that the next generation of these compounds could perform much better. Suzetrigine could be approved by early 2025.

    Hi Impact
    Vertex PharmaceuticalsSuzetrigineHealthcare
  • Innovative drug with novel mechanism may revolutionize schizophrenia treatment, potentially affecting healthcare spending.

    Schizophrenia is one of the costliest mental health illnesses - it costs nearly $300 billion dollars in healthcare spending annually despite affecting less than 1% of the population. It is currently treated with antipsychotics, a treatment discovered through pure chance. Regulators are currently deciding whether to approve a drug with a novel mechanism for treating schizophrenia. The new drug has opened up a new hypothesis for schizophrenia, which multiple biotech companies are pursuing.

    Hi Impact
    Healthcare
  • New injectable HIV-prevention drug shows high efficacy but comes with a steep price.

    The results from a landmark pair of major clinical trials of lenacapavir, an injectable HIV-prevention drug that only requires dosing every six months, show that it is 89% more effective at preventing HIV than daily oral preventative medication among gay, bisexual, and transgender people. It could be a game changer if rolled out broadly and equitably, but the drug is extraordinarily expensive. Its current list price for use as an HIV treatment is $3,450 per month. It is unclear whether it will have a different list price for use as a preventive.

    Hi Impact
    lenacapavirHealthcare
Month Summary
Technology
  • OpenAI is considering a new subscription model for its upcoming AI product, Strawberry, while also restructuring for better financial backing.
  • Telegram founder
  • The startup landscape is shifting towards more tech-intensive ventures, with a focus on specialized research and higher capital requirements.
  • Boom Supersonic's XB-1 demonstrator aircraft successfully completed its second flight, testing new systems for future supersonic travel.
  • announced the uncrewed return of Boeing's Starliner, with future crewed missions planned for 2025.
  • OpenAI's SearchGPT aims to compete with Google Search by providing AI-driven information retrieval, though it currently faces accuracy issues.
  • Tesla is preparing to unveil its autonomous robotaxi technology at an event in Los Angeles, indicating ongoing challenges in achieving full autonomy.
  • The US Department of Justice is investigating Nvidia for potential antitrust violations related to its AI chip market dominance.
  • Apple plans to use OLED screens in all iPhone 16 models, moving away from Japanese suppliers and introducing new AI features.
  • Amazon S3 has introduced conditional writes to prevent overwriting existing objects, simplifying data updates for developers.
  • Chinese scientists have developed a hydrogel that shows promise in treating osteoarthritis by restoring cartilage lubrication.
  • Nvidia's CEO is working to position the Nvidia as a comprehensive provider for data center needs, amidst growing competition from AMD and Intel.
  • OpenAI
  • Nvidia Blackwell
  • Amazon is set to release a revamped Alexa voice assistant in October, powered by AI models from Anthropic's Claude, and will be offered as a paid subscription service.